Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920 · Bristol-Myers Squibb · PHASE4 · terminated · last registry update 2026-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business objectives have changed” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Phase 3 first posted: AbbVie, Upadacitinib + Placebo for Upadacitinib (NCT07896434)
- 2026-10-16Results posted on the registry: Julie Nangia, Ruxolitinib + Placebo (for Ruxolitinib) (NCT02928978)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-09-16Also stopped (terminated): Ryvu Therapeutics SA, RVU120 + Ruxolitinib (NCT06397313)
- 2026-08-27Phase 3 first posted: Bristol-Myers Squibb, Deucravacitinib (NCT07791199)
- 2026-08-26Results posted on the registry: Mayo Clinic, Deucravacitinib (NCT06444399)
- 2026-08-19Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT07772492)
- 2026-08-13Results posted on the registry: AbbVie, ABT-494 (NCT02782663)
- 2026-08-04Results posted on the registry: Syntara, PXS-5505 (NCT04676529)
- 2026-07-27Results posted on the registry: Alfasigma S.p.A., Filgotinib + Placebo to match filgotinib (NCT03025308)
- 2026-07-24Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQH3906 capsules + Deucravacitinib tablets 6 mg (NCT07724366)
- 2026-07-23Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Ruxolitinib (NCT07722611)
- 2026-07-16Results posted on the registry: Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-16Also stopped (terminated): Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-15Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Ruxolitinib (NCT05998408)
- 2026-07-15Also stopped (terminated): Alfasigma S.p.A., Filgotinib + Filgotinib (NCT06222034)
- 2026-07-09Results posted on the registry: Massachusetts General Hospital, Ruxolitinib (NCT03427866)
- 2026-07-07Results posted on the registry: Tu Dan, Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (NCT04906746)
- 2026-06-29Results posted on the registry: University of Texas Southwestern Medical Center, Tofacitinib 10mg + Temozolomide (NCT05326464)
- 2026-06-26Also stopped (terminated): Incyte Corporation, itacitinib (NCT04640025)
- 2026-06-25Results posted on the registry: Janssen Research & Development, LLC, JNJ-77242113 + JNJ-77242113 Matching Placebo (NCT06143878)
- 2026-06-25Results posted on the registry: Janssen Research & Development, LLC, JNJ-77242113 + JNJ-77242113 Matching Placebo (NCT06220604)
- 2026-06-22Results posted on the registry: Mayo Clinic, Rifaximin + Placebo (NCT04254549)
- 2026-06-22Also stopped (terminated): Mayo Clinic, Rifaximin + Placebo (NCT04254549)
- 2026-06-04Results posted on the registry: Constellation Pharmaceuticals, Pelabresib + Ruxolitinib (NCT02158858)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision